Create
Learn
Share

Test 4

rename
wasabi's version from 2015-04-28 00:02

Section

Question Answer
imatinib - gleevecbcr-abl inhibitor. multikinase inhibits KIT, PDGFR, Abl
niloginib - tasignabcr-abl inhibitor. multikinase inhibits KIT, PDGFR, Abl. more potent than imatinib
bosutinib - bosulif bcr-abl inhibitor. multikinase inhibits KIT, PDGFR, Abl. more potent than imatinib
dasatinib - spyrel bcr-abl inhibitor. multikinase inhibits KIT, PDGFR, Abl. more potent than imatinib
ponatinib - iclusigbcr-abl inhibitor. multikinase inhibits KIT, PDGFR, Abl. more potent than imatinib. bind to Abl, FGFR1, FLT3, VEGRF2, inhibits T315I mutation
omacetaxine - synriboprotein synthesis inhibitor
cetuximab - erbituxEGFR inhibitor
panitumumab - vectibixEGFR inhibitor
erlotinib - tarcevaEGFR inhibitor
geftinib - iressaEGFR inhibitor
afatinib - gilotrifEGFR inhibitor. also HER2. pan-HER inhibitor. irreversibly inhibit HER1, HER2, HER4
memorize

section

Question Answer
crizotinib - xalkoriALK inhibitor. binds to ALK, MET
certinib - zykadiaALK inhibitor, binds to ALK. CYP3A4, Pgp. NSCLC with ALK fusion
trastuzumab - herceptinHER2 inhibitor
pertuzumab - perjetaHER2 inhibitor
ado-trastuzumab emtansineHER2 inhibitor
lapatinib - tykerbHER2 inhibitor. also EGFR (HER1/ERBB1)
bevacizumab - avastinVEGF inhibitor
ziv-afibercept - zaltrapVEGF inhibitor
ramucirumab - cyramzaVEGF inhibitor
memorize

section

Question Answer
ibrutinib - imbruvicaBTK inhibitor (bruton's tyrosine kinase inhibitor)
vemurafenib - zelborafBRAF kinase inhibitor. binds to BRAF (melanoma with BRAF V600 mutations)
dabrafenib - tafinlarBRAF kinase inhibitor. binds to BRAF (melanoma with BRAF V600 mutations)
trametinib - mekinistMEK inhibitor (melanoma with BRAF V600 mutation)
vismodegib - erivedgehedgehog pathway inhibitor (SMO, PTCH)
idelaisib - zydeligPI3K delta inhibitor
olaparib - lynparzaPARP inhibitor. monotherapy. only drug specific for BRCA1 or 2
nivolumab - opdivoPD1/PD-L1 inhibitor. OPD1VO. melanoma. NSCLC
pembrolizumab - keytrudaPD1/PD-L1 inhibitor
ipilimumab - yervoyCTLA 4 inhibitor
azacitidine - vidazaDNA methylation inhibitor. epigenetic inhibitor
decitabine - dacogen DNA methylation inhibitor. epigenetic inhibitor
belinostat - beleodaqhistone deacetylase inhibitor (HDAc inhibitor). epigenetic inhibitor
panobinostat - farydakhistone deacetylase inhibitor (HDAc inhibitor). epigenetic inhibitor
romidepsin - istodaxhistone deacetylase inhibitor (HDAc inhibitor). epigenetic inhibitor
vorinostat - zolinzahistone deacetylase inhibitor (HDAc inhibitor). epigenetic inhibitor
memorize

section

Question Answer
bortezomib - velcadeproteasome inhibitor
carfilzomib - kyprolisproteasome inhibitor
everolimus - afinitormTOR kinase inhibitor
temsirolimus - toriselmTOR kinase inhibitor
lanalidomide - revlimidangiogenesis inhibitor. immunomodulatory agent
pomalidomide - pomalystangiogenesis inhibitor. immunomodulatory agent
thalidomide - thalomidangiogenesis inhibitor. immunomodulatory agent
palbociclib - ibrancecdk4/6 inhibitors. combo w/letrozole (aromatase inhibitor) for ER+ HER2- breast cancer
sipulence-T - Provengedendritic cell vaccine
ibritumomab tiuxetan - zevalinanti CD20
obinutuzumab - gazyvaanti CD20
ofatumumab - arzerraanti CD20
rituximab - rituxan, mabtheraanti CD20
brentuximab vedotin - adcetrisconjugate monoclonal antibody + MMAE. binds and blocks CD30
blinatumomab - blincytobispecific T cell engager antibody. CD19 (T cells), CD3 (B cells)
dinutuximab - unituxin anti GD2 antibody
lenvatinib - levimamulti tyrosine kinase inhibitor (VEGF, FGF, PDGF, KIT, RET). thyroid cancer
memorize

Recent badges